BlueWillow Biologics raised a round of funding on November 28, 2012. Investors include Perseus.
BlueWillow Biologics develops and commercializes intranasal vaccines using its patented NanoVax® technology platform. The technology employs an oil-in-water nanoemulsion adjuvant that is effective wh…
